Literature DB >> 10414450

Serum beta-2-microglobulin, TNF-alpha and interleukins in myeloproliferative disorders.

K L Bourantas1, E C Hatzimichael, A C Makis, A Chaidos, E D Kapsali, S Tsiara, A Mavridis.   

Abstract

Whereas beta-2-microglobulin (beta2M) has mainly been used as a prognostic factor in patients with lymphoproliferative disorders, some studies have reported the value of beta2M in myeloproliferative disorders (MPD). In order to investigate a potential role in the pathogenesis of MPD and to find a possible value as indicators in monitoring the course of the disease, we measured beta2M, TNF-alpha, IL-1alpha, IL-1beta, IL-2, sIL-2R, IL-6 and IL-10 in 55 patients with MPD, at diagnosis and during the course of the disease. In progressive disease and particularly when transformation to acute leukemia occurred, high levels of beta2M, IL-2 and sIL-2R were found in all patients; the elevation was progressive, which suggests a potential prognostic usefulness in the individual patient.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10414450     DOI: 10.1111/j.1600-0609.1999.tb01845.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  8 in total

1.  Association of plasma adiponectin concentrations with chronic lymphocytic leukemia and myeloproliferative diseases.

Authors:  Ferit Avcu; A Ugur Ural; M Ilker Yilmaz; Necati Bingol; Oral Nevruz; Kayser Caglar
Journal:  Int J Hematol       Date:  2006-04       Impact factor: 2.490

2.  The serum levels of soluble interleukin-2 receptor alpha and lactate dehydrogenase but not of B2-microglobulin correlate with selected clinico-pathological prognostic factors and response to therapy in childhood soft tissue sarcomas.

Authors:  Ewa Bien; Malgorzata Rapala; Malgorzata Krawczyk; Anna Balcerska
Journal:  J Cancer Res Clin Oncol       Date:  2009-08-20       Impact factor: 4.553

Review 3.  The Microenvironment in Myeloproliferative Neoplasms.

Authors:  Gajalakshmi Ramanathan; Angela G Fleischman
Journal:  Hematol Oncol Clin North Am       Date:  2020-12-09       Impact factor: 3.722

Review 4.  Cytokines frequently implicated in myeloproliferative neoplasms.

Authors:  Yingying Wang; Xuelan Zuo
Journal:  Cytokine X       Date:  2019-03-27

Review 5.  Inflammatory Pathophysiology as a Contributor to Myeloproliferative Neoplasms.

Authors:  Daniel Arthur Corpuz Fisher; Jared Scott Fowles; Amy Zhou; Stephen Tracy Oh
Journal:  Front Immunol       Date:  2021-06-01       Impact factor: 8.786

6.  Neopterin and beta-2 microglobulin relations to immunity and inflammatory status in nonischemic dilated cardiomyopathy patients.

Authors:  Celina Wojciechowska; Jan Wodniecki; Romuald Wojnicz; Ewa Romuk; Wojciech Jacheć; Andrzej Tomasik; Bronisława Skrzep-Poloczek; Beata Spinczyk; Ewa Nowalany-Kozielska
Journal:  Mediators Inflamm       Date:  2014-08-18       Impact factor: 4.711

Review 7.  Circulating Cytokine Levels as Markers of Inflammation in Philadelphia Negative Myeloproliferative Neoplasms: Diagnostic and Prognostic Interest.

Authors:  Julie Mondet; Kais Hussein; Pascal Mossuz
Journal:  Mediators Inflamm       Date:  2015-10-07       Impact factor: 4.711

Review 8.  Cytokine Profiling in Myeloproliferative Neoplasms: Overview on Phenotype Correlation, Outcome Prediction, and Role of Genetic Variants.

Authors:  Elena Masselli; Giulia Pozzi; Giuliana Gobbi; Stefania Merighi; Stefania Gessi; Marco Vitale; Cecilia Carubbi
Journal:  Cells       Date:  2020-09-21       Impact factor: 6.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.